<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291525</url>
  </required_header>
  <id_info>
    <org_study_id>2005-01</org_study_id>
    <secondary_id>G050208</secondary_id>
    <nct_id>NCT00291525</nct_id>
  </id_info>
  <brief_title>Randomized On-X Anticoagulation Trial</brief_title>
  <acronym>PROACT</acronym>
  <official_title>Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>On-X Life Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Acelis Connected Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>On-X Life Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various patient groups with the On-X Valve can be maintained safely on lower doses of blood
      thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard
      dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a longitudinal, randomized (randomization to occur at the 3-month follow-up) study
      comparing the On-X valve on low dose anticoagulation (test group) to concomitant control
      groups of On-X valves receiving standard Coumadin/aspirin therapy, and also to FDA objective
      performance criteria (OPC) for heart valve replacement. It is a multicenter study consisting
      of up to 50 centers in the United States, Canada, and Italy enrolling and randomizing no more
      than 1200 patients (200 in each of 6 groups). There are three test arms of the study: low
      risk aortic valve replacement, high risk aortic valve replacement, and mitral valve
      replacement. Each arm has an equivalent control. Test therapies are: low risk aortic valve
      replacement - aspirin/Plavix, high risk aortic valve replacement - Coumadin at INR of 1.5 to
      2.0 plus aspirin, and mitral valve replacement - Coumadin at an INR of 2.0 to 2.5 plus
      aspirin. Follow-up will run for up to 8 years in each patient. Each arm is independent and
      the low risk aortic and high risk aortic arms are completed. The low risk aortic arm was
      closed early resulting in a reduction of the estimated total enrollment with randomization to
      1000. The high risk arm is completed with FDA review and this arm had 375 randomized
      enrollees. The mitral arm continues to enroll with a planned randomized enrollment of 400.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2006</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thromboembolism</measure>
    <time_frame>8 years</time_frame>
    <description>Rate of thromboembolism evaluated every 100 patient-years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Valve Thrombosis</measure>
    <time_frame>8 years</time_frame>
    <description>Rate of thrombosis evaluated every 100 patient-years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>8 years</time_frame>
    <description>Rate of major and minor bleeding events evaluated every 100 patient-years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Valve-Related Events</measure>
    <time_frame>8 years</time_frame>
    <description>Rates of other valve-related events (e.g. prosthetic valve dysfunction, hemolysis, hemolytic anemia, endocarditis) every 100 patient-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) classification</measure>
    <time_frame>8 years</time_frame>
    <description>Functional classification at each follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve Hemodynamics</measure>
    <time_frame>5 years</time_frame>
    <description>Echocardiograpic measures of valve hemodynamics at 1, 3 and 5 years</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>AVR Low Risk without warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVR Low Risk without warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVR low risk with standard warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AVR low risk with standard warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVR High risk with lower warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVR High risk with lower warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVR High Risk with standard warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AVR High Risk with standard warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVR with lower warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVR with lower warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVR with standard warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MVR with standard warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On-X valve using reduced anticoagulation</intervention_name>
    <description>Valve replacement with antiplatelet agents or lowered warfarin</description>
    <arm_group_label>AVR High risk with lower warfarin</arm_group_label>
    <arm_group_label>AVR Low Risk without warfarin</arm_group_label>
    <arm_group_label>MVR with lower warfarin</arm_group_label>
    <other_name>On-X Prosthetic Heart Valve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On-X Valve with Standard warfarin Therapy</intervention_name>
    <description>Valve replacement with standard dosage warfarin</description>
    <arm_group_label>AVR High Risk with standard warfarin</arm_group_label>
    <arm_group_label>AVR low risk with standard warfarin</arm_group_label>
    <arm_group_label>MVR with standard warfarin</arm_group_label>
    <other_name>On-X Prosthetic Heart Valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring isolated aortic valve replacement (AVR), or isolated mitral valve
             replacement (MVR).

          -  AVR patients receiving low dose or antiplatelet only anticoagulation will be divided
             into groups at low risk and high risk for thromboembolism with all patients being in
             the low risk group except for patients with the following conditions which place a
             patient in the high risk group:

               -  Chronic atrial fibrillation

               -  Left ventricular ejection fraction &lt; 30 %

               -  Enlarged left atrium &gt;50mm diameter

               -  Spontaneous echo contrasts in the left atrium

               -  Vascular pathology

               -  Neurological events

               -  Hypercoagulability

               -  Left or right ventricular aneurysm

               -  Lack of platelet response to aspirin or clopidogrel

               -  Women receiving estrogen replacement therapy

          -  Concomitant cardiac surgery is allowed

          -  Adult patients

        Exclusion Criteria:

          -  Right side valve replacement

          -  Double (aortic plus mitral) valve replacement

          -  Patients with active endocarditis at the time of implant

          -  Previous confirmed or suspected thromboembolic event or thrombophlebitis

          -  Other terminal illness

          -  Patients who are in an emergency state

          -  Inability to return for required follow-ups

          -  Patients with an On-X valve implanted within the study and subsequently explanted

          -  Patients who are known to be pregnant, plan to become pregnant or are lactating

          -  Patients with acquired immunodeficiency syndrome or know to be HIV positive

          -  Patients who are prison inmates or known drug or alcohol abusers

          -  Patients unable to give adequate informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Puskas, MD</last_name>
    <role>Study Director</role>
    <affiliation>MOUNT SINAI HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tucson Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Health Care Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Heart &amp; Vascular Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Hospital - University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Surgical Associates</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Heart &amp; Lung</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Heart Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital - Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma/VA Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Heart &amp; Vascular Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White - Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>78093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Washington Hospital</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>76G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCPQ Chirurgie Cardiaque</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Puskas JD; PROACT Investigators. Reply: Low-Thrombogenicity Mechanical Heart Valves: Which Antithrombotic Strategy? J Am Coll Cardiol. 2018 Oct 9;72(15):1879-1880. doi: 10.1016/j.jacc.2018.07.063.</citation>
    <PMID>30286937</PMID>
  </reference>
  <results_reference>
    <citation>Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L, McGrath M, Kong B, Hughes C, Sethi G, Wait M, Martin T, Graeve A; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014 Apr;147(4):1202-1210; discussion 1210-1. doi: 10.1016/j.jtcvs.2014.01.004. Epub 2014 Jan 12.</citation>
    <PMID>24512654</PMID>
  </results_reference>
  <results_reference>
    <citation>Yanagawa B, Levitsky S, Puskas JD; PROACT Investigators. Reduced anticoagulation is safe in high-risk patients with the On-X mechanical aortic valve. Curr Opin Cardiol. 2015 Mar;30(2):140-145. doi: 10.1097/HCO.0000000000000149.</citation>
    <PMID>29504958</PMID>
  </results_reference>
  <results_reference>
    <citation>Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, Copeland J, Quinn R, Hughes GC, Azar H, McGrath M, Wait M, Kong B, Martin T, Douville EC, Meyer S, Ye J, Jamieson WRE, Landvater L, Hagberg R, Trotter T, Armitage J, Askew J, Accola K, Levy P, Duncan D, Yanagawa B, Ely J, Graeve A; PROACT Investigators. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. J Am Coll Cardiol. 2018 Jun 19;71(24):2717-2726. doi: 10.1016/j.jacc.2018.03.535.</citation>
    <PMID>29903344</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>valve</keyword>
  <keyword>prosthesis</keyword>
  <keyword>antithrombotics</keyword>
  <keyword>randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

